JP7731344B2 - デング熱及びa型肝炎を予防するための方法 - Google Patents
デング熱及びa型肝炎を予防するための方法Info
- Publication number
- JP7731344B2 JP7731344B2 JP2022509723A JP2022509723A JP7731344B2 JP 7731344 B2 JP7731344 B2 JP 7731344B2 JP 2022509723 A JP2022509723 A JP 2022509723A JP 2022509723 A JP2022509723 A JP 2022509723A JP 7731344 B2 JP7731344 B2 JP 7731344B2
- Authority
- JP
- Japan
- Prior art keywords
- dengue
- serotype
- vaccine
- hepatitis
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024177535A JP2025032070A (ja) | 2019-08-16 | 2024-10-09 | デング熱及びa型肝炎を予防するための方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IDP00201907241 | 2019-08-16 | ||
| IDPID2019-07241 | 2019-08-16 | ||
| EP19195692.9 | 2019-09-05 | ||
| USPCT/US2019/049749 | 2019-09-05 | ||
| US16/561,953 US11590221B2 (en) | 2018-09-05 | 2019-09-05 | Dengue vaccine unit dose and administration thereof |
| EP19195692.9A EP3620174B1 (en) | 2018-09-05 | 2019-09-05 | Dengue vaccine unit dose and administration thereof |
| PCT/US2019/049749 WO2020051334A1 (en) | 2018-09-05 | 2019-09-05 | Dengue vaccine unit dose and administration thereof |
| US16/561,953 | 2019-09-05 | ||
| PCT/US2020/020991 WO2021034349A1 (en) | 2019-08-16 | 2020-03-04 | Methods for preventing dengue and hepatitis a |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024177535A Division JP2025032070A (ja) | 2019-08-16 | 2024-10-09 | デング熱及びa型肝炎を予防するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022544613A JP2022544613A (ja) | 2022-10-19 |
| JP2022544613A5 JP2022544613A5 (cg-RX-API-DMAC7.html) | 2023-03-09 |
| JP7731344B2 true JP7731344B2 (ja) | 2025-08-29 |
Family
ID=74660757
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022509723A Active JP7731344B2 (ja) | 2019-08-16 | 2020-03-04 | デング熱及びa型肝炎を予防するための方法 |
| JP2024177535A Pending JP2025032070A (ja) | 2019-08-16 | 2024-10-09 | デング熱及びa型肝炎を予防するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024177535A Pending JP2025032070A (ja) | 2019-08-16 | 2024-10-09 | デング熱及びa型肝炎を予防するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4013451A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7731344B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220049023A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114555113A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2020331884B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022001476A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3147807A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022001742A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12022550261A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021034349A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260167703A1 (en) * | 2022-11-02 | 2026-06-18 | Takeda Vaccines, Inc. | A method for determining the infectivity of a virus |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2345614T3 (es) | 1997-02-28 | 2010-09-28 | Sanofi Pasteur Biologics Co. | Vacunas quimericas de flavivirus. |
| AU2003239932A1 (en) | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
| WO2007021672A2 (en) | 2005-08-10 | 2007-02-22 | Acambis Inc. | Vaccination against dengue virus infection |
| FR2903605A1 (fr) | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| DK2054428T3 (da) | 2006-08-15 | 2013-08-26 | Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Hea | Udvikling af bestanddele til denque-virus-vaccine |
| FR2906724B1 (fr) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
| EP2931310A4 (en) * | 2012-12-14 | 2016-05-25 | Takeda Vaccines Inc | COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS |
| TWI852899B (zh) * | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| EP3316905A1 (en) * | 2015-07-03 | 2018-05-09 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
| JP2019511533A (ja) * | 2016-04-13 | 2019-04-25 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法 |
| TWI766876B (zh) | 2016-08-03 | 2022-06-11 | 美商武田疫苗股份有限公司 | 用於與經改良之調配物一起穩定黃病毒的組成物及方法 |
-
2020
- 2020-03-04 WO PCT/US2020/020991 patent/WO2021034349A1/en not_active Ceased
- 2020-03-04 PH PH1/2022/550261A patent/PH12022550261A1/en unknown
- 2020-03-04 AU AU2020331884A patent/AU2020331884B2/en active Active
- 2020-03-04 EP EP20719243.6A patent/EP4013451A1/en active Pending
- 2020-03-04 MX MX2022001742A patent/MX2022001742A/es unknown
- 2020-03-04 KR KR1020227008716A patent/KR20220049023A/ko active Pending
- 2020-03-04 CN CN202080071928.2A patent/CN114555113A/zh active Pending
- 2020-03-04 JP JP2022509723A patent/JP7731344B2/ja active Active
- 2020-03-04 BR BR112022001476A patent/BR112022001476A2/pt unknown
- 2020-03-04 CA CA3147807A patent/CA3147807A1/en active Pending
-
2024
- 2024-10-09 JP JP2024177535A patent/JP2025032070A/ja active Pending
-
2025
- 2025-04-23 AU AU2025202876A patent/AU2025202876B2/en active Active
-
2026
- 2026-04-15 AU AU2026202847A patent/AU2026202847A1/en active Pending
Non-Patent Citations (6)
| Title |
|---|
| Bock, H. L. et al.,Does the concurrent administration of an inactivated hepatitis A vaccine influence the immune response to other travelers vaccines?, Journal of Travel Medicine,2000年,Vol.7, No.2,p.74-78,doi:10.2310/7060.2000.00025 |
| History of Changes for Study: NCT03525119,ClinicalTrials.gov archive [online],2018年05月03日,[検索日 2024.03.28], Retrieved from the Internet: <https://classic.clinicaltrials.gov/ct2/history/NCT03525119?V_1> |
| Osorio, J. E. et al.,Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques,The American Journal of Tropical Medicine and Hygiene,2011年,Vol.84, No.6,p.978-987,doi:10.4269/ajtmh.2011.10-0592 |
| Rinderknecht, S. et al.,Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age,The Pediatric Infectious Disease Journal,2011年,Vol.30, No.10,p.e179-e185,doi:10.1097/INF.0b013e31822256a5 |
| Saez-Llorens, X. et al.,Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study,The Lancet. Infectious Diseases,2017年,Vol.17, No.6,p.615-625,doi:10.1016/S1473-3099(17)30166-4 |
| Sridhar, S. et al.,Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy,The New England Journal of Medicine,2018年07月26日,Vol.379, No.4,p.327-340,doi:10.1056/NEJMoa1800820 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2026202847A1 (en) | 2026-05-07 |
| WO2021034349A1 (en) | 2021-02-25 |
| JP2022544613A (ja) | 2022-10-19 |
| JP2025032070A (ja) | 2025-03-11 |
| AU2020331884B2 (en) | 2025-01-23 |
| KR20220049023A (ko) | 2022-04-20 |
| PH12022550261A1 (en) | 2023-06-26 |
| AU2025202876B2 (en) | 2026-01-29 |
| MX2022001742A (es) | 2022-04-07 |
| EP4013451A1 (en) | 2022-06-22 |
| CN114555113A (zh) | 2022-05-27 |
| BR112022001476A2 (pt) | 2023-10-03 |
| CA3147807A1 (en) | 2021-02-25 |
| AU2020331884A1 (en) | 2022-03-03 |
| AU2025202876A1 (en) | 2025-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7791925B2 (ja) | デング熱ワクチン単位用量及びその投与 | |
| US10946087B2 (en) | Vaccine compositions against dengue virus diseases | |
| US20230233628A1 (en) | Dengue vaccine unit dose and administration thereof | |
| AU2026202847A1 (en) | Methods For Preventing Dengue And Yellow Fever | |
| US12201683B2 (en) | Methods for preventing dengue and hepatitis a | |
| WO2025072259A9 (en) | Coadministration of tetravalent dengue vaccine with hpv vaccine | |
| HK40082761A (en) | Dengue vaccine unit dose and administration thereof | |
| HK40023196A (en) | Dengue vaccine unit dose and administration thereof | |
| HK40023196B (en) | Dengue vaccine unit dose and administration thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220413 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20220413 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230301 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230301 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240409 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240702 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240725 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241009 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250212 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250509 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250710 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250722 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250819 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7731344 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |